Elanco Animal Health (ELAN)

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two compa...

Investors need to pay close attention to ELAN stock based on the movements in the options market lately.

Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with ba...

Leerink analyst Daniel Clark raised the firm's price target on Elanco to $11 from $9.50 and keeps a Market Perform rating on the shares. The firm says the company's quarter was solid, and its exposure...

Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and ...

Elanco Animal Health Incorporated   ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year.

While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metr...

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a ye...

Elanco Animal Health Incorporated ELAN on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the hu...